AGP Picks
View all

Perspectify logo Perspectify News

Labels

Read articles from across the media landscape with news outlet bias labels for added context. Learn about labels.

Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

DWP reminds PIP claimants of strict four-week holiday rule to avoid penalties

DWP reminds PIP claimants of strict four-week holiday rule to avoid penalties

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Nordic initiative signals new approach to tackling drug resistance [Advocacy Lab]

Nordic initiative signals new approach to tackling drug resistance [Advocacy Lab]

Morning Minute: Unplugged

Morning Minute: Unplugged

EFTA–Vietnam FTA Concluded: Business Implications for Trade, Investment, and Market Access

EFTA–Vietnam FTA Concluded: Business Implications for Trade, Investment, and Market Access

Indian passport ranking drops from 75 to 81 in latest Henley Passport Index 2026

Indian passport ranking drops from 75 to 81 in latest Henley Passport Index 2026

The rise of the public media detractor

The rise of the public media detractor

The Small Suffer What They Must?

The Small Suffer What They Must?

UK reveals important test foreign applicants must pass during British citizenship application

UK reveals important test foreign applicants must pass during British citizenship application

Little-known rules for PIP claimants taking holidays this summer

Little-known rules for PIP claimants taking holidays this summer

WHO’s Role in Stopping Cross-Border Infections

WHO’s Role in Stopping Cross-Border Infections

The Morning Briefing: Rally Trump Is Still My Favorite Trump

The Morning Briefing: Rally Trump Is Still My Favorite Trump

I made a tool to predict EES queues – here’s how to avoid the worst delays

I made a tool to predict EES queues – here’s how to avoid the worst delays

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

DAYBU®  Recommended for Approval in the European Union by CHMP

DAYBU® Recommended for Approval in the European Union by CHMP

A comprehensive guide to supplementary protection certificates in Europe as regulation controversy heats up 

A comprehensive guide to supplementary protection certificates in Europe as regulation controversy heats up 

The Swiss approach to prosecuting and litigating supplementary protection certificates 

The Swiss approach to prosecuting and litigating supplementary protection certificates 

Why this ASX biotech stock is soaring 30% today

Why this ASX biotech stock is soaring 30% today

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.